RxDoctor Payments DataLook up a doctor →

Sheba Joseph, MD

Family Medicine · Tulsa, OKNPI 1104082908

Payments from drug & device makers

$16,020in general payments, 2019–2025

Across 1,079 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$971
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$16,014100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,020 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$43,843
Medicare patients
153
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$110,523
JardianceEmpagliflozin58$64,757
EliquisApixaban61$48,609
JanuviaSitagliptin Phosphate38$44,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$24,575
FarxigaDapagliflozin Propanediol13$20,463
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$19,385
UbrelvyUbrogepant14$15,979
LinzessLinaclotide11$11,659
Tresiba Flextouch U-100Insulin Degludec11$7,834
Rosuvastatin Calcium158$7,377
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,327
SymbicortBudesonide/Formoterol Fumarate22$6,870
Atorvastatin Calcium296$6,223
MyrbetriqMirabegron12$5,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,808$110,52374 claims
Boehringer IngelheimJardiance$759$64,75758 claims
PfizerEliquis$685$48,60961 claims
MerckJanuvia$493$44,85138 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,800$34,66046 claims
AbbVieUbrelvy, Linzess$1,563$27,63725 claims
GSKTrelegy Ellipta$1,614$24,57531 claims
Astellas Pharma US IncMyrbetriq$236$5,54512 claims
Almatica Pharma LLCSertraline Hcl$12$1,825123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →